These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9266624)

  • 21. Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?
    Denissen NH; Peters JG; Masereeuw R; Barrera P
    Scand J Rheumatol; 2008; 37(1):72-4. PubMed ID: 18189198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulphasalazine and lung toxicity.
    Parry SD; Barbatzas C; Peel ET; Barton JR
    Eur Respir J; 2002 Apr; 19(4):756-64. PubMed ID: 11999006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years.
    Ferraccioli GF; Gremese E; Tomietto P; Favret G; Damato R; Di Poi E
    Rheumatology (Oxford); 2002 Aug; 41(8):892-8. PubMed ID: 12154206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine.
    Farr M; Symmons DP; Bacon PA
    Ann Rheum Dis; 1985 Nov; 44(11):798-800. PubMed ID: 2865931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of sulfasalazine and hydroxichloroqine hepatotoxicity in patients with rheumatic arthritis and isolated HBS-antigen positivity].
    Petrov AV
    Lik Sprava; 2004; (1):60-5. PubMed ID: 17051718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis.
    Nurmohamed MT; Soesan M; van Oers MH; Dijkmans BA; van Soesbergen RM
    Rheumatology (Oxford); 2000 Dec; 39(12):1431-3. PubMed ID: 11136894
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.
    van Riel PL; van Gestel AM; van de Putte LB
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():40-2. PubMed ID: 8535648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
    van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
    Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abrupt occurrence of high fever and rash in a patient treated with sulphasalazine for psoriatic arthritis.
    Fischetti F; Gerloni R; Bardelli M; Carretta R
    Minerva Med; 2003 Dec; 94(6):437-44. PubMed ID: 14976471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study.
    Lee HJ; Waller RD; Stebbings S; Highton J; Orlovich DA; Schmierer D; Fawcett JP
    Int J Rheum Dis; 2010 Feb; 13(1):48-54. PubMed ID: 20374384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulphasalazine in the treatment of children with chronic arthritis.
    Huang JL; Chen LC
    Clin Rheumatol; 1998; 17(5):359-63. PubMed ID: 9805178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sulfasalazine neurotoxicity].
    Chadenat ML; Morelon S; Dupont C; Dechy H; Raffin-Sanson ML; Dorra M; Rouveix E
    Ann Med Interne (Paris); 2001 Jun; 152(4):283-4. PubMed ID: 11474379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
    Clegg DO; Reda DJ; Abdellatif M
    Arthritis Rheum; 1999 Nov; 42(11):2325-9. PubMed ID: 10555027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Life-threatening liver failure and severe dyscrasias in blood and lymph nodes caused by sulphasalazine].
    Kampmann P; Højlyng N; Pedersen M
    Ugeskr Laeger; 2006 Sep; 168(39):3331-3. PubMed ID: 17032600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Toxic epidermal necrolysis during therapy with sulphasalazine in a patient with arthritis. Case report].
    Rachwał-Siek K; Ponikowska M; Wiland P
    Wiad Lek; 2011; 64(4):283-7. PubMed ID: 22533153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of sulfasalazine in rheumatic diseases.
    Fuchs HA
    Bull Rheum Dis; 1997 Nov; 46(7):3-4. PubMed ID: 9366125
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatotoxicity after treatment with sulfasalazine.
    Haines JD
    Postgrad Med; 1986 May; 79(6):193-4, 197-8. PubMed ID: 2871549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulphasalazine: a 'new' antirheumatic drug.
    Pullar T; Capell HA
    Br J Rheumatol; 1984 Feb; 23(1):26-34. PubMed ID: 6141832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sulfasalazine treatment on serum immunoglobulin levels in children with juvenile chronic arthritis.
    van Rossum MA; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA; van Soesbergen RM;
    Scand J Rheumatol; 2001; 30(1):25-30. PubMed ID: 11252688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis].
    Mundo A; Pedone V; Lamanna G; Cervini C
    Clin Ter; 1997; 148(1-2):7-13. PubMed ID: 9377840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.